Omnicare to pay $50 million to resolve allegations
Omnicare, the largest institutional pharmacy provider in the U.S., agreed to pay $50 million to resolve allegations that some of its pharmacies improperly dispensed controlled substances. The settlement resolves allegations that Cincinnati-based Omnicare violated the Controlled Substances Act, the U.S. Justice Department said in a news release. The government alleged the pharmacies routinely dispensed controlled substances to residents of long-term-care facilities without a signed or oral prescription from a practitioner, dispensed controlled substances using incomplete prescriptions, and did not properly document partially filled prescriptions. “These practices are alltoo-prevalent in the long-term-care industry and are a violation of federal law,” Steven Dettelbach, U.S. attorney for the Northern District of Ohio, said in a news release. Omnicare admitted no wrongdoing, according to the settlement. Omnicare said in a news release that the settlement contains no allegations or findings that controlled substances were unlawfully diverted or patients were harmed. “We believe this settlement provides long-term-care pharmacies, long-term-care facilities and prescribers with clear direction regarding the procedures that must be followed when dispensing controlled substances,” Omnicare CEO John Figueroa said in the release.